The landmark FLOW study shows the benefits extend to kidney, cardiovascular, and mortality outcomes in high-risk patients with type 2 diabetes and CKD.
-like peptide-1 receptor agonist, has shown significant benefits in preventing major kidney disease , cardiovascular events, as well as mortality in patients with
The study, conducted in 28 countries, involved 3533 patients recruited between June 2019 and May 2021 who had CKD and type 2 diabetes. Patients were randomized to treatment with semaglutide 1.0 mg once weekly or placebo , both in addition to standard care.
"These findings offer great promise in reshaping treatment strategies for individuals at high risk of diabetes-related complications, offering a new avenue for kidney and cardiovascular protection," he said during his talk.Among the important aspects of the study was the high rate of patients receiving cardiovascular treatment, said current ERA President Christoph Wanner, MD, who provided an independent perspective during the session.
"The number of participants on SGLT2 inhibitors was low and results were nonconclusive for this reason," he said. Therefore,"this trial does not answer the question of whether semaglutide adds benefit for the primary endpoint for patients who are already on the standard of care, ie, SGLT2 inhibitors."
"I think the question is: What benefit do we get when we prescribe in combination? is looking at that issue of whether the effects are additive, and we believe they are," he said. As many as 537 million people worldwide have type 2 diabetes. In addition, four out of 10 people with type 2 diabetes and three out of 10 people with
Chronic Kidney Failure CKD - Chronic Kidney Disease Chronic Kidney Disease CKD Renal Failure Renal Insufficiency Kidney Insufficiency Kidney Failure Renal Impairment Kidneys Renal Disease Kidney Disease Kidney Disorder Renal Disorder Nephropathy Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Hemodialysis
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Ozempic Drug Semaglutide Could Cut Heart Risk By 20%—Regardless Of Weight Loss, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Semaglutide Aids Weight Loss With or Without Bariatric SurgeryMeaningful weight loss was seen with the use of semaglutide, regardless of whether people had previous weight loss surgery, a first-of-its-kind study revealed.
Read more »
Genetic Test Can Predict Response to Semaglutide for Weight LossWith an assist from machine learning, investigators find a genetic test that can identify obesity phenotypes and predict who will benefit most from semaglutide for weight loss.
Read more »
Everything you need to know about semaglutide weight loss drugsThe semaglutide-based medicines Ozempic and Wegovy can help people who are obese or overweight to quickly lose weight, but questions remain over how long they should be taken and what other effects they may have
Read more »
Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT DataSemaglutide remains effective for weight loss at 4 years in people with preexisting cardiovascular disease and overweight/obesity but without T2D and provides CV benefits regardless of weight.
Read more »